Hématologie
MENUToxicité cardiaque des inhibiteurs du protéasome Volume 25, numéro 6, Novembre-Décembre 2019
- [1] Li W., Garcia D., Cornell R.F. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. JAMA Oncol. 2017;3:980-988.
- [2] Cornell R.F., Ky B., Weiss B.M. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 2019;37:1946-1955.